Publication:
Immune monitoring of a child with autoimmune hepatitis and type 1 diabetes during COVID-19 infection

dc.contributor.kuauthorYüksel, Muhammed
dc.contributor.kuauthorAktürk, Hacer
dc.contributor.kuauthorArıkan, Çiğdem
dc.contributor.kuprofileResearcher
dc.contributor.kuprofileFaculty Member
dc.contributor.kuprofileFaculty Member
dc.contributor.researchcenterKoç University Research Center for Translational Medicine (KUTTAM) / Koç Üniversitesi Translasyonel Tıp Araştırma Merkezi (KUTTAM)
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.unitKoç University Hospital
dc.contributor.yokidN/A
dc.contributor.yokidN/A
dc.contributor.yokid240198
dc.date.accessioned2024-11-09T13:45:42Z
dc.date.issued2020
dc.description.abstractImmunocompromised patients may be at increased risk to develop COVID-19 during the 2019 β-coronavirus infection. We present the unique opportunity we had to monitor the liver, IL-6 and immune cell course before, during and after COVID-19 in a boy with autoimmune hepatitis (AIH) and type 1 diabetes (T1D). CD4+and CD8+T cells frequencies decreased because of prednisolone, followed by a plateauing increase whereas CD19+CD20+B cell increased strongly and was unaffected by COVID-19 infection. Moreover, the percentage of activated CD8+T cells expressing HLA-DR (CD8+HLA-DR+) increased during COVID-19 and subsided after its clearance. Total regulatory T cells (Tregs: CD4+CD25+CD127lowFOXP3+) remained stable. Although activated Tregs (CD4+CD45RA-FOXP3high) strongly increased upon prednisolone, it decreased afterwards. Furthermore, regulatory B cells (Bregs: CD19+CD20+CD24highCD38high) declined sharply owing to prednisolone. Serum IL-6 remained undetectable at all times. We demonstrated for the first time immune monitoring in a child with AIH and T1D before, during and after COVID-19. We hypothesize that continuing with low level of prednisolone without azathioprine may have abrogated activated Tregs, Bregs and IL-6 production and therefore permitting the activation of CD8+T cells, clearing the virus.
dc.description.fulltextYES
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue9
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipKoç University Seeds Funding 2019–2021
dc.description.versionPublisher version
dc.description.volume32
dc.formatpdf
dc.identifier.doi10.1097/MEG.0000000000001804
dc.identifier.eissn1473-5687
dc.identifier.embargoNO
dc.identifier.filenameinventorynoIR02374
dc.identifier.issn0954-691X
dc.identifier.linkhttps://doi.org/10.1097/MEG.0000000000001804
dc.identifier.quartileQ4
dc.identifier.scopus2-s2.0-85089127035
dc.identifier.urihttps://hdl.handle.net/20.500.14288/3643
dc.identifier.wos562738600025
dc.keywords2019-β-coronavirus
dc.keywordsAutoimmune hepatitis
dc.keywordsCOVID-19
dc.keywordsImmunosuppression
dc.keywordsInterleukin-6
dc.keywordsRegulatory B cells
dc.keywordsRegulatory T cells
dc.keywordsType 1 diabetes mellitus
dc.languageEnglish
dc.publisherLippincott Williams and Wilkins (LWW)
dc.relation.grantnoNA
dc.relation.urihttp://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/9010
dc.sourceEuropean Journal of Gastroenterology _ Hepatology
dc.subjectMedicine
dc.subjectGastroenterology and hepatology
dc.titleImmune monitoring of a child with autoimmune hepatitis and type 1 diabetes during COVID-19 infection
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.authoridN/A
local.contributor.authoridN/A
local.contributor.authorid0000-0002-0794-2741
local.contributor.kuauthorYüksel, Muhammed
local.contributor.kuauthorAktürk, Hacer
local.contributor.kuauthorArıkan, Çiğdem

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
9010.pdf
Size:
437.42 KB
Format:
Adobe Portable Document Format